ID

38843

Beskrivning

Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment; ODM derived from: https://clinicaltrials.gov/show/NCT00795600

Länk

https://clinicaltrials.gov/show/NCT00795600

Nyckelord

Versioner (1)
  1. 2019-11-09 2019-11-09 -
Rättsinnehavare

See clinicaltrials.gov

Uppladdad den

9 november 2019

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Diabetes NCT00795600

Engelsk

Eligibility Diabetes NCT00795600

1 Formulär  
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT00795600
Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
subjects with type 2 diabetes who have been treated with 2 or 3 doses of insulin (one of them must be a premix) for at least 3 months prior to inclusion in trial
Beskrivning

Diabetes Mellitus, Non-Insulin-Dependent | Insulin Dose Quantity | Premixed insulin

Datatyp

boolean

Alias
UMLS CUI [1]
C0011860
UMLS CUI [2,1]
C0021641
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C1265611
UMLS CUI [3]
C2069057
glycosylated haemoglobin (hba1c) between 7.0-11.0 %
Beskrivning

Hemoglobin A1c measurement

Datatyp

boolean

Alias
UMLS CUI [1]
C0474680
body mass index (bmi) between 27.5-40 kg/m^2
Beskrivning

Body mass index

Datatyp

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
treatment with any oral antidiabetic drugs (oads) in the last 6 months except metformin (subjects currently treated with metformin within the interval of 1000 -
Beskrivning

Antidiabetics Oral | Exception Metformin

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0935929
UMLS CUI [1,2]
C1527415
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0025598
2550 mg daily may be included in the trial. the dose should have remained unchanged for a period of 2 months prior to randomisation and should be expected to remain unchanged throughout the trial period)
Beskrivning

Eligibility | Metformin Dose U/day | Dose unchanged

Datatyp

boolean

Alias
UMLS CUI [1]
C1548635
UMLS CUI [2,1]
C0025598
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0456683
UMLS CUI [3,1]
C0178602
UMLS CUI [3,2]
C0442739
use of approved weight lowering pharmacotherapy (e.g. orlistat, sibutramin, rimonabant) or obesity induced by drug treatment (e.g. corticosteroids, non-steroidal anti-inflammatory drugs (nsaids), tricyclic anti-depressants, atypical anti-psychotics)
Beskrivning

Weight-Loss Agents | orlistat | sibutramine | rimonabant | Obesity Pharmacotherapy Induced | Adrenal Cortex Hormones | Anti-Inflammatory Agents, Non-Steroidal | Tricyclic Antidepressive Agents | Atypical antipsychotic

Datatyp

boolean

Alias
UMLS CUI [1]
C0376606
UMLS CUI [2]
C0076275
UMLS CUI [3]
C0074493
UMLS CUI [4]
C1142933
UMLS CUI [5,1]
C0028754
UMLS CUI [5,2]
C0013216
UMLS CUI [5,3]
C0205263
UMLS CUI [6]
C0001617
UMLS CUI [7]
C0003211
UMLS CUI [8]
C0003290
UMLS CUI [9]
C1276996
previous or planned surgical treatment of obesity
Beskrivning

Obesity surgery | Obesity surgery Planned

Datatyp

boolean

Alias
UMLS CUI [1]
C1167841
UMLS CUI [2,1]
C1167841
UMLS CUI [2,2]
C1301732
total daily insulin dose higher or equal 2 iu/kg
Beskrivning

Insulin Cumulative Dose u/day

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0021641
UMLS CUI [1,2]
C2986497
UMLS CUI [1,3]
C0456683
proliferative retinopathy or maculopathy that has required acute treatment within the last six months
Beskrivning

Proliferative retinopathy Treatment required for | Disorder of macula of retina Treatment required for

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0339467
UMLS CUI [1,2]
C0332121
UMLS CUI [2,1]
C0730362
UMLS CUI [2,2]
C0332121
receipt of any investigational drug within 1 month prior to this trial
Beskrivning

Investigational New Drugs

Datatyp

boolean

Alias
UMLS CUI [1]
C0013230
cardiac disease defined according to new york heart association (nyha) class iii or iv, unstable angina pectoris and/or myocardial infarction within the last 6 months previous to the selection
Beskrivning

Heart Disease New York Heart Association Classification | Angina, Unstable | Myocardial Infarction

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0018799
UMLS CUI [1,2]
C1275491
UMLS CUI [2]
C0002965
UMLS CUI [3]
C0027051
Tillbaka till toppen

Similar models

Eligibility Diabetes NCT00795600

1 Formulär
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT00795600
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent | Insulin Dose Quantity | Premixed insulin
Item
subjects with type 2 diabetes who have been treated with 2 or 3 doses of insulin (one of them must be a premix) for at least 3 months prior to inclusion in trial
boolean
C0011860 (UMLS CUI [1])
C0021641 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C2069057 (UMLS CUI [3])
Hemoglobin A1c measurement
Item
glycosylated haemoglobin (hba1c) between 7.0-11.0 %
boolean
C0474680 (UMLS CUI [1])
Body mass index
Item
body mass index (bmi) between 27.5-40 kg/m^2
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Antidiabetics Oral | Exception Metformin
Item
treatment with any oral antidiabetic drugs (oads) in the last 6 months except metformin (subjects currently treated with metformin within the interval of 1000 -
boolean
C0935929 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0025598 (UMLS CUI [2,2])
Eligibility | Metformin Dose U/day | Dose unchanged
Item
2550 mg daily may be included in the trial. the dose should have remained unchanged for a period of 2 months prior to randomisation and should be expected to remain unchanged throughout the trial period)
boolean
C1548635 (UMLS CUI [1])
C0025598 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0456683 (UMLS CUI [2,3])
C0178602 (UMLS CUI [3,1])
C0442739 (UMLS CUI [3,2])
Weight-Loss Agents | orlistat | sibutramine | rimonabant | Obesity Pharmacotherapy Induced | Adrenal Cortex Hormones | Anti-Inflammatory Agents, Non-Steroidal | Tricyclic Antidepressive Agents | Atypical antipsychotic
Item
use of approved weight lowering pharmacotherapy (e.g. orlistat, sibutramin, rimonabant) or obesity induced by drug treatment (e.g. corticosteroids, non-steroidal anti-inflammatory drugs (nsaids), tricyclic anti-depressants, atypical anti-psychotics)
boolean
C0376606 (UMLS CUI [1])
C0076275 (UMLS CUI [2])
C0074493 (UMLS CUI [3])
C1142933 (UMLS CUI [4])
C0028754 (UMLS CUI [5,1])
C0013216 (UMLS CUI [5,2])
C0205263 (UMLS CUI [5,3])
C0001617 (UMLS CUI [6])
C0003211 (UMLS CUI [7])
C0003290 (UMLS CUI [8])
C1276996 (UMLS CUI [9])
Obesity surgery | Obesity surgery Planned
Item
previous or planned surgical treatment of obesity
boolean
C1167841 (UMLS CUI [1])
C1167841 (UMLS CUI [2,1])
C1301732 (UMLS CUI [2,2])
Insulin Cumulative Dose u/day
Item
total daily insulin dose higher or equal 2 iu/kg
boolean
C0021641 (UMLS CUI [1,1])
C2986497 (UMLS CUI [1,2])
C0456683 (UMLS CUI [1,3])
Proliferative retinopathy Treatment required for | Disorder of macula of retina Treatment required for
Item
proliferative retinopathy or maculopathy that has required acute treatment within the last six months
boolean
C0339467 (UMLS CUI [1,1])
C0332121 (UMLS CUI [1,2])
C0730362 (UMLS CUI [2,1])
C0332121 (UMLS CUI [2,2])
Investigational New Drugs
Item
receipt of any investigational drug within 1 month prior to this trial
boolean
C0013230 (UMLS CUI [1])
Heart Disease New York Heart Association Classification | Angina, Unstable | Myocardial Infarction
Item
cardiac disease defined according to new york heart association (nyha) class iii or iv, unstable angina pectoris and/or myocardial infarction within the last 6 months previous to the selection
boolean
C0018799 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
C0002965 (UMLS CUI [2])
C0027051 (UMLS CUI [3])
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial